Narcolepsy

Individuals with narcolepsy were significantly more likely to have sleep, mood and pain disorders compared with matched controls, indicating where treatment may best target common comorbidities, according to new research from Sleep Advances.

The FDA has approved a supplemental new drug application for a once-daily, extended-release therapeutic to treat cataplexy or excessive daytime sleepiness in patients with narcolepsy aged 7 years and older, according to the manufacturer.

People with narcolepsy were more likely than propensity score-matched people without narcolepsy to develop heart disease, regardless of sleep apnea status, according to a retrospective cohort study.

Takeda has reported positive results from a phase 2b clinical trial of an investigational, oral orexin receptor agonist for narcolepsy type 1.

Takeda has announced positive topline results from a phase 2b trial evaluating an oral orexin receptor 2 agonist to treat individuals with narcolepsy type 1.

INDIANAPOLIS — Machine learning models predict the likelihood of type 1 narcolepsy with a high degree of accuracy, opening the door to increased access to testing and care, according to a speaker at SLEEP 2023.

INDIANAPOLIS — For adults with narcolepsy, a switch in treatment to Xywav was safe, efficacious and preferred over treatment with Xyrem on a gram-for-gram basis, according to Wayne Macfadden, MD, in a Healio video from SLEEP 2023.